Abstract:
Ertapenem is a sterile, synthetic, parenteral, I-~ methyl-carbapenem that is
structurally related to beta-lactam antibiotics. Ertapenem, a Group 1 carbapenem, is
most recently introduced into the market and cover both Gram positive and Gram
negative pathogens. Here the objective is to find the characteristics of ertapenem in
the treatment of complicated infectious diseases and establish demonstrated safety
profile and clinical efficacy of ertapenem against complicated diseases. This report is
fully based on secondary data which I have collected from many journals, IMS,
MIMS, browsing different web sites. From this research it was found that ertapenem
shows excellent success in complicated infectious diseases. By doing market strategy
regarding IMS data it is assume that if it is launched in the market the total market
size will be 31,087,084 within 1-2 years which makes the drug feasible in the market.
Description:
This thesis submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy (B.Pharm) in East West University, Dhaka, Bangladesh.